A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects

Despite the fact that multiple sclerosis (MS) and Alzheimer's disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluate...

Full description

Saved in:
Bibliographic Details
Published inJournal of neuroinflammation Vol. 11; no. 1; p. 30
Main Authors Grimaldi, Luigi Maria, Zappalà, Giuseppe, Iemolo, Francesco, Castellano, Anna, Ruggieri, Stefano, Bruno, Giuseppe, Paolillo, Andrea
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 13.02.2014
BioMed Central
Subjects
Activities of daily living
Adjuvants, Immunologic - therapeutic use
Advertising executives
Aged
Alzheimer Disease - drug therapy
Alzheimer's disease
Analysis of Variance
Antidepressants
Antilipemic agents
Blood-brain barrier
Cholesterol
Double-Blind Method
Family medical history
Female
Free radicals
Hematology
Humans
Interferon beta-1a
Interferon-beta - therapeutic use
Male
Mental Status Schedule
Middle Aged
Neuropsychological Tests
Older people
Pathogenesis
Physiological aspects
Pilot Projects
Proteins
Retrospective Studies
Statins
Time Factors
Treatment Outcome
Italy
Germany
Online AccessGet full text

Cover

Abstract Despite the fact that multiple sclerosis (MS) and Alzheimer's disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFNβ1a in subjects affected by mild-to-moderate AD in a double-blind, randomized, placebo-controlled, multicenter pilot study. Forty-two early Alzheimer's patients were randomized to receive either a 22 mcg subcutaneous injection of IFNβ1a or placebo three times per week. A treatment period of 28 weeks was followed by 24 weeks of observation. IFNβ1a was well tolerated and adverse events were infrequent and mild to moderate. Although not statistically significant, a reduction in disease progression during follow-up was measured in IFNβ1a-treated patients by the Alzheimer's Disease Assessment Scale cognitive subscale. Interestingly, the treatment group showed significant improvements in the Instrumental Activities of Daily Living and Physical Self-maintenance Scale. This study suggests that IFNβ1a is safe and well tolerated in early AD patients, and its possible beneficial role should be further investigated in larger studies.
AbstractList Despite the fact that multiple sclerosis (MS) and Alzheimer's disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFNβ1a in subjects affected by mild-to-moderate AD in a double-blind, randomized, placebo-controlled, multicenter pilot study. Forty-two early Alzheimer's patients were randomized to receive either a 22 mcg subcutaneous injection of IFNβ1a or placebo three times per week. A treatment period of 28 weeks was followed by 24 weeks of observation. IFNβ1a was well tolerated and adverse events were infrequent and mild to moderate. Although not statistically significant, a reduction in disease progression during follow-up was measured in IFNβ1a-treated patients by the Alzheimer's Disease Assessment Scale cognitive subscale. Interestingly, the treatment group showed significant improvements in the Instrumental Activities of Daily Living and Physical Self-maintenance Scale. This study suggests that IFNβ1a is safe and well tolerated in early AD patients, and its possible beneficial role should be further investigated in larger studies.Despite the fact that multiple sclerosis (MS) and Alzheimer's disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFNβ1a in subjects affected by mild-to-moderate AD in a double-blind, randomized, placebo-controlled, multicenter pilot study. Forty-two early Alzheimer's patients were randomized to receive either a 22 mcg subcutaneous injection of IFNβ1a or placebo three times per week. A treatment period of 28 weeks was followed by 24 weeks of observation. IFNβ1a was well tolerated and adverse events were infrequent and mild to moderate. Although not statistically significant, a reduction in disease progression during follow-up was measured in IFNβ1a-treated patients by the Alzheimer's Disease Assessment Scale cognitive subscale. Interestingly, the treatment group showed significant improvements in the Instrumental Activities of Daily Living and Physical Self-maintenance Scale. This study suggests that IFNβ1a is safe and well tolerated in early AD patients, and its possible beneficial role should be further investigated in larger studies.
Despite the fact that multiple sclerosis (MS) and Alzheimer's disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFNβ1a in subjects affected by mild-to-moderate AD in a double-blind, randomized, placebo-controlled, multicenter pilot study. Forty-two early Alzheimer's patients were randomized to receive either a 22 mcg subcutaneous injection of IFNβ1a or placebo three times per week. A treatment period of 28 weeks was followed by 24 weeks of observation. IFNβ1a was well tolerated and adverse events were infrequent and mild to moderate. Although not statistically significant, a reduction in disease progression during follow-up was measured in IFNβ1a-treated patients by the Alzheimer's Disease Assessment Scale cognitive subscale. Interestingly, the treatment group showed significant improvements in the Instrumental Activities of Daily Living and Physical Self-maintenance Scale. This study suggests that IFNβ1a is safe and well tolerated in early AD patients, and its possible beneficial role should be further investigated in larger studies.
Despite the fact that multiple sclerosis (MS) and Alzheimer's disease (AD) share common neuroimmunological features, interferon beta 1a (IFN[beta]1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFN[beta]1a in subjects affected by mild-to-moderate AD in a double-blind, randomized, placebo-controlled, multicenter pilot study. Forty-two early Alzheimer's patients were randomized to receive either a 22 mcg subcutaneous injection of IFN[beta]1a or placebo three times per week. A treatment period of 28 weeks was followed by 24 weeks of observation. IFN[beta]1a was well tolerated and adverse events were infrequent and mild to moderate. Although not statistically significant, a reduction in disease progression during follow-up was measured in IFN[beta]1a-treated patients by the Alzheimer's Disease Assessment Scale cognitive subscale. Interestingly, the treatment group showed significant improvements in the Instrumental Activities of Daily Living and Physical Self-maintenance Scale. This study suggests that IFN[beta]1a is safe and well tolerated in early AD patients, and its possible beneficial role should be further investigated in larger studies.
Despite the fact that multiple sclerosis (MS) and Alzheimer's disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFNβ1a in subjects affected by mild-to-moderate AD in a double-blind, randomized, placebo-controlled, multicenter pilot study. Forty-two early Alzheimer's patients were randomized to receive either a 22 mcg subcutaneous injection of IFNβ1a or placebo three times per week. A treatment period of 28 weeks was followed by 24 weeks of observation. IFNβ1a was well tolerated and adverse events were infrequent and mild to moderate. Although not statistically significant, a reduction in disease progression during follow-up was measured in IFNβ1a-treated patients by the Alzheimer's Disease Assessment Scale cognitive subscale. Interestingly, the treatment group showed significant improvements in the Instrumental Activities of Daily Living and Physical Self-maintenance Scale. This study suggests that IFNβ1a is safe and well tolerated in early AD patients, and its possible beneficial role should be further investigated in larger studies.
Doc number: 30 Abstract: Despite the fact that multiple sclerosis (MS) and Alzheimer's disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFNβ1a in subjects affected by mild-to-moderate AD in a double-blind, randomized, placebo-controlled, multicenter pilot study. Forty-two early Alzheimer's patients were randomized to receive either a 22 mcg subcutaneous injection of IFNβ1a or placebo three times per week. A treatment period of 28 weeks was followed by 24 weeks of observation. IFNβ1a was well tolerated and adverse events were infrequent and mild to moderate. Although not statistically significant, a reduction in disease progression during follow-up was measured in IFNβ1a-treated patients by the Alzheimer's Disease Assessment Scale cognitive subscale. Interestingly, the treatment group showed significant improvements in the Instrumental Activities of Daily Living and Physical Self-maintenance Scale. This study suggests that IFNβ1a is safe and well tolerated in early AD patients, and its possible beneficial role should be further investigated in larger studies.
Despite the fact that multiple sclerosis (MS) and Alzheimer's disease (AD) share common neuroimmunological features, interferon beta 1a (IFN[beta]1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFN[beta]1a in subjects affected by mild-to-moderate AD in a double-blind, randomized, placebo-controlled, multicenter pilot study. Forty-two early Alzheimer's patients were randomized to receive either a 22 mcg subcutaneous injection of IFN[beta]1a or placebo three times per week. A treatment period of 28 weeks was followed by 24 weeks of observation. IFN[beta]1a was well tolerated and adverse events were infrequent and mild to moderate. Although not statistically significant, a reduction in disease progression during follow-up was measured in IFN[beta]1a-treated patients by the Alzheimer's Disease Assessment Scale cognitive subscale. Interestingly, the treatment group showed significant improvements in the Instrumental Activities of Daily Living and Physical Self-maintenance Scale. This study suggests that IFN[beta]1a is safe and well tolerated in early AD patients, and its possible beneficial role should be further investigated in larger studies. Keywords: Alzheimer's disease, clinical trials, randomized, controlled, multiple sclerosis, interferon
Audience Academic
Author Iemolo, Francesco
Paolillo, Andrea
Zappalà, Giuseppe
Bruno, Giuseppe
Ruggieri, Stefano
Castellano, Anna
Grimaldi, Luigi Maria
AuthorAffiliation 2 U.V.A. Neurologia, Azienda Ospedaliera Garibaldi-Nesima, Via Palermo 135, 95122 Catania, Italy
6 MerckSerono S.A., Merck Serono-Italy An affiliate of Merck KGA, Darmsdadt, Germany, Via Casilina 125, 00176 Roma, Italy
3 U.O.C. Provinciale di Neurologia, Via Papa Giovanni XIII, 97019 Vittoria, RG, Italy
1 U.O. di Neurologia, Fondazione Istituto San Raffaele “G. Giglio” di Cefalù, Contrada Pietrapollastra, 90015 Cefalù, PA, Italy
4 Clinica Neurologica, IRCCS Neuromed, Via Atinense, 18, 86077 Pozzilli, IS, Italy
5 Centro U.V.A., Dipartimento di Scienze Neurologiche, Università degli Studi di Roma “La Sapienza”, Viale dell’Università, 30, 00185 Roma, Italy
AuthorAffiliation_xml – name: 5 Centro U.V.A., Dipartimento di Scienze Neurologiche, Università degli Studi di Roma “La Sapienza”, Viale dell’Università, 30, 00185 Roma, Italy
– name: 6 MerckSerono S.A., Merck Serono-Italy An affiliate of Merck KGA, Darmsdadt, Germany, Via Casilina 125, 00176 Roma, Italy
– name: 3 U.O.C. Provinciale di Neurologia, Via Papa Giovanni XIII, 97019 Vittoria, RG, Italy
– name: 1 U.O. di Neurologia, Fondazione Istituto San Raffaele “G. Giglio” di Cefalù, Contrada Pietrapollastra, 90015 Cefalù, PA, Italy
– name: 2 U.V.A. Neurologia, Azienda Ospedaliera Garibaldi-Nesima, Via Palermo 135, 95122 Catania, Italy
– name: 4 Clinica Neurologica, IRCCS Neuromed, Via Atinense, 18, 86077 Pozzilli, IS, Italy
Author_xml – sequence: 1
  givenname: Luigi Maria
  surname: Grimaldi
  fullname: Grimaldi, Luigi Maria
– sequence: 2
  givenname: Giuseppe
  surname: Zappalà
  fullname: Zappalà, Giuseppe
– sequence: 3
  givenname: Francesco
  surname: Iemolo
  fullname: Iemolo, Francesco
– sequence: 4
  givenname: Anna
  surname: Castellano
  fullname: Castellano, Anna
– sequence: 5
  givenname: Stefano
  surname: Ruggieri
  fullname: Ruggieri, Stefano
– sequence: 6
  givenname: Giuseppe
  surname: Bruno
  fullname: Bruno, Giuseppe
– sequence: 7
  givenname: Andrea
  surname: Paolillo
  fullname: Paolillo, Andrea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24524367$$D View this record in MEDLINE/PubMed
BookMark eNqNkk9rFDEYxoNU7B89e5MBL71Mmz8zyeQirMWqUPCiXkMmeaebZWayJhlhe_Jr-PX8JM2wde2WFiSHhCe_5-Hl4T1GB6MfAaHXBJ8R0vBzIipaUiyrkpCS4WfoaKcc3HsfouMYVxgzWnP6Ah3SqqYV4-IIfV8Ua9f7VMQ02U3hxyItoZgiFL4r3JggdBCy2kLSJdFZKkCHflMs-psluAHCn1-_Y2FdBJ1NcWpXYFJ8iZ53uo_w6u4-Qd8uP3y9-FReffn4-WJxVbZ1g1NZWdta4LbmlmJMOXAsjRGys13TApfS1BUIwMJgEFYQbKvWamYpMULTTrMT9G6bu57aAayBMQXdq3Vwgw4b5bVT-z-jW6pr_1MxyUhuIwe83wa0zj8RsP9j_KDmXtXcqyJEMZxDTu-mCP7HBDGpwUUDfa9H8FNUpMY1qxpZNf-DkoaJWsiMvn2ArvwUxlznTGHJMZXkH3Wte1Bu7Hwe08yhalEzyXkjRJWps0eofCwMzuSd6lzW9wxv7he7K-Tv5mTgfAuY4GMM0O0QgtW8m4-0VD9wGJd0cn4u1vVP-m4BQeHm6g
CitedBy_id crossref_primary_10_1136_jnnp_2017_316201
crossref_primary_10_1590_1980_57642018dn13_010002
crossref_primary_10_3390_cancers14225495
crossref_primary_10_3390_ijms232214394
crossref_primary_10_1186_s12974_024_03298_y
crossref_primary_10_3310_hta21260
crossref_primary_10_3390_jpm11111116
crossref_primary_10_3389_fimmu_2021_738511
crossref_primary_10_1016_j_jneuroim_2023_578031
crossref_primary_10_1016_j_jns_2017_03_031
crossref_primary_10_2174_1874467213666200422090135
crossref_primary_10_1038_s41582_020_00435_y
crossref_primary_10_1111_cen3_12518
crossref_primary_10_3233_JAD_200607
crossref_primary_10_1016_j_brainresbull_2019_06_015
crossref_primary_10_1186_s12974_019_1417_4
crossref_primary_10_1016_j_drudis_2022_01_004
crossref_primary_10_1517_14728222_2014_989834
crossref_primary_10_3233_JAD_171131
crossref_primary_10_1016_j_ebiom_2022_104175
crossref_primary_10_1016_j_jaut_2014_08_002
crossref_primary_10_1186_s12974_020_01877_3
crossref_primary_10_1093_brain_awv408
crossref_primary_10_1016_j_drudis_2019_05_009
crossref_primary_10_1016_j_ejphar_2024_176882
crossref_primary_10_1002_glia_23460
crossref_primary_10_1016_j_bbadis_2022_166430
crossref_primary_10_3389_fnagi_2022_968444
crossref_primary_10_18632_oncoscience_309
crossref_primary_10_1097_WNR_0000000000001132
crossref_primary_10_1186_s12859_016_1065_y
crossref_primary_10_3389_fneur_2021_658695
crossref_primary_10_1016_j_pnpbp_2019_109661
crossref_primary_10_1038_s41398_018_0355_8
crossref_primary_10_1007_s12031_018_1249_1
crossref_primary_10_1080_1744666X_2023_2248391
crossref_primary_10_1016_j_coph_2015_09_015
crossref_primary_10_1016_j_mehy_2022_110996
crossref_primary_10_1177_1179573517722512
crossref_primary_10_1002_alz_13076
crossref_primary_10_3233_JAD_215125
Cites_doi 10.1001/archneur.62.4.563
10.1038/nature08983
10.1191/1352458505ms1144oa
10.1089/rej.2009.0993
10.1111/j.1749-6632.1999.tb07821.x
10.1001/archneur.60.8.1119
10.1212/WNL.51.3.682
10.1016/S0165-5728(99)00029-6
10.1136/jnnp-2012-304740
10.1097/00062752-199901000-00004
10.1016/0165-0173(95)00011-9
10.1146/annurev.neuro.30.051606.094313
10.1016/S0165-5728(99)00106-X
10.1177/1352458509350309
10.1016/j.expneurol.2006.04.015
10.1016/j.mcn.2010.08.001
10.1073/pnas.86.19.7611
10.1002/ana.1218
10.1152/physrev.00023.2009
ContentType Journal Article
Copyright COPYRIGHT 2014 BioMed Central Ltd.
2014 Grimaldi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Copyright © 2014 Grimaldi et al.; licensee BioMed Central Ltd. 2014 Grimaldi et al.; licensee BioMed Central Ltd.
Copyright_xml – notice: COPYRIGHT 2014 BioMed Central Ltd.
– notice: 2014 Grimaldi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
– notice: Copyright © 2014 Grimaldi et al.; licensee BioMed Central Ltd. 2014 Grimaldi et al.; licensee BioMed Central Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7TK
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1186/1742-2094-11-30
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

AIDS and Cancer Research Abstracts

MEDLINE

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1742-2094
EndPage 30
ExternalDocumentID PMC3931325
oai_biomedcentral_com_1742_2094_11_30
3226274671
A539668774
24524367
10_1186_1742_2094_11_30
Genre Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Italy
Germany
GeographicLocations_xml – name: Germany
– name: Italy
GroupedDBID ---
0R~
29L
2VQ
2WC
4.4
53G
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
INH
INR
IPNFZ
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RIG
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7T5
7TK
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
-A0
ABVAZ
ACRMQ
ADINQ
AFGXO
AFNRJ
C24
5PM
ID FETCH-LOGICAL-b580t-4ddbde6d56d20026e609cc79fdf8be699c54e7e07c0e7d710d4bda3d21c7a2fa3
IEDL.DBID RBZ
ISSN 1742-2094
IngestDate Thu Aug 21 14:21:46 EDT 2025
Wed May 22 07:13:25 EDT 2024
Fri Jul 11 00:50:51 EDT 2025
Sun Aug 24 03:24:59 EDT 2025
Fri Jul 25 02:43:47 EDT 2025
Tue Jun 17 22:05:28 EDT 2025
Tue Jun 10 21:03:04 EDT 2025
Mon Jul 21 05:35:18 EDT 2025
Tue Jul 01 02:54:23 EDT 2025
Thu Apr 24 23:10:16 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b580t-4ddbde6d56d20026e609cc79fdf8be699c54e7e07c0e7d710d4bda3d21c7a2fa3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ObjectType-Article-2
ObjectType-Feature-1
OpenAccessLink http://dx.doi.org/10.1186/1742-2094-11-30
PMID 24524367
PQID 1500960291
PQPubID 55345
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3931325
biomedcentral_primary_oai_biomedcentral_com_1742_2094_11_30
proquest_miscellaneous_1505348948
proquest_miscellaneous_1501837579
proquest_journals_1500960291
gale_infotracmisc_A539668774
gale_infotracacademiconefile_A539668774
pubmed_primary_24524367
crossref_primary_10_1186_1742_2094_11_30
crossref_citationtrail_10_1186_1742_2094_11_30
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-02-13
PublicationDateYYYYMMDD 2014-02-13
PublicationDate_xml – month: 02
  year: 2014
  text: 2014-02-13
  day: 13
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of neuroinflammation
PublicationTitleAlternate J Neuroinflammation
PublicationYear 2014
Publisher BioMed Central Ltd
BioMed Central
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
References 10.1186/1742-2094-11-30-B14
10.1186/1742-2094-11-30-B25
10.1186/1742-2094-11-30-B13
10.1186/1742-2094-11-30-B24
10.1186/1742-2094-11-30-B16
10.1186/1742-2094-11-30-B26
10.1186/1742-2094-11-30-B10
10.1186/1742-2094-11-30-B23
10.1186/1742-2094-11-30-B2
10.1186/1742-2094-11-30-B3
10.1186/1742-2094-11-30-B4
10.1186/1742-2094-11-30-B5
10.1186/1742-2094-11-30-B6
10.1186/1742-2094-11-30-B18
10.1186/1742-2094-11-30-B7
10.1186/1742-2094-11-30-B17
10.1186/1742-2094-11-30-B9
10.1186/1742-2094-11-30-B19
10.1186/1742-2094-11-30-B1
15824253 - Arch Neurol. 2005 Apr;62(4):563-8
20393191 - Physiol Rev. 2010 Apr;90(2):465-94
23544717 - Am J Manag Care. 2013 Feb2013;19(2 Suppl):S21-7
19995846 - Mult Scler. 2010 Jan;16(1):68-77
11601495 - Ann Neurol. 2001 Oct;50(4):443-51
18558855 - Annu Rev Neurosci. 2008;31:247-69
20336135 - Nature. 2010 Mar 25;464(7288):529-35
20182045 - J Alzheimers Dis. 2010;21(1):1-14
23595944 - J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1186-91
20462385 - Rejuvenation Res. 2010 Apr-Jun;13(2-3):301-13
8866675 - Brain Res Brain Res Rev. 1995 Sep;21(2):195-218
2529544 - Proc Natl Acad Sci U S A. 1989 Oct;86(19):7611-5
16764858 - Exp Neurol. 2006 Sep;201(1):172-81
12925369 - Arch Neurol. 2003 Aug;60(8):1119-22
10496186 - J Neuroimmunol. 1999 Sep 1;99(1):131-41
20696249 - Mol Cell Neurosci. 2010 Dec;45(4):408-17
9551903 - J Immunol. 1998 Jan 15;160(2):681-90
15794391 - Mult Scler. 2005 Apr;11(2):175-81
23001712 - J Alzheimers Dis. 2013;33(2):297-312
9915549 - Curr Opin Hematol. 1999 Jan;6(1):15-24
9126051 - Brain. 1997 Mar;120 ( Pt 3):393-9
10672233 - Ann N Y Acad Sci. 1999;893:113-25
10496180 - J Neuroimmunol. 1999 Sep 1;99(1):82-90
11971121 - Neurology. 2002 Apr 23;58(8 Suppl 4):S3-9
18728744 - Neuropsychiatr Dis Treat. 2008 Apr;4(2):321-36
9748010 - Neurology. 1998 Sep;51(3):682-9
References_xml – ident: 10.1186/1742-2094-11-30-B17
  doi: 10.1001/archneur.62.4.563
– ident: 10.1186/1742-2094-11-30-B1
  doi: 10.1038/nature08983
– ident: 10.1186/1742-2094-11-30-B23
  doi: 10.1191/1352458505ms1144oa
– ident: 10.1186/1742-2094-11-30-B24
  doi: 10.1089/rej.2009.0993
– ident: 10.1186/1742-2094-11-30-B7
  doi: 10.1111/j.1749-6632.1999.tb07821.x
– ident: 10.1186/1742-2094-11-30-B2
  doi: 10.1001/archneur.60.8.1119
– ident: 10.1186/1742-2094-11-30-B14
  doi: 10.1212/WNL.51.3.682
– ident: 10.1186/1742-2094-11-30-B13
  doi: 10.1016/S0165-5728(99)00029-6
– ident: 10.1186/1742-2094-11-30-B26
  doi: 10.1136/jnnp-2012-304740
– ident: 10.1186/1742-2094-11-30-B4
  doi: 10.1097/00062752-199901000-00004
– ident: 10.1186/1742-2094-11-30-B5
  doi: 10.1016/0165-0173(95)00011-9
– ident: 10.1186/1742-2094-11-30-B10
  doi: 10.1146/annurev.neuro.30.051606.094313
– ident: 10.1186/1742-2094-11-30-B9
  doi: 10.1016/S0165-5728(99)00106-X
– ident: 10.1186/1742-2094-11-30-B19
  doi: 10.1177/1352458509350309
– ident: 10.1186/1742-2094-11-30-B18
  doi: 10.1016/j.expneurol.2006.04.015
– ident: 10.1186/1742-2094-11-30-B25
  doi: 10.1016/j.mcn.2010.08.001
– ident: 10.1186/1742-2094-11-30-B6
  doi: 10.1073/pnas.86.19.7611
– ident: 10.1186/1742-2094-11-30-B16
  doi: 10.1002/ana.1218
– ident: 10.1186/1742-2094-11-30-B3
  doi: 10.1152/physrev.00023.2009
– reference: 20696249 - Mol Cell Neurosci. 2010 Dec;45(4):408-17
– reference: 18728744 - Neuropsychiatr Dis Treat. 2008 Apr;4(2):321-36
– reference: 10672233 - Ann N Y Acad Sci. 1999;893:113-25
– reference: 16764858 - Exp Neurol. 2006 Sep;201(1):172-81
– reference: 23001712 - J Alzheimers Dis. 2013;33(2):297-312
– reference: 20393191 - Physiol Rev. 2010 Apr;90(2):465-94
– reference: 11971121 - Neurology. 2002 Apr 23;58(8 Suppl 4):S3-9
– reference: 23544717 - Am J Manag Care. 2013 Feb2013;19(2 Suppl):S21-7
– reference: 8866675 - Brain Res Brain Res Rev. 1995 Sep;21(2):195-218
– reference: 19995846 - Mult Scler. 2010 Jan;16(1):68-77
– reference: 9748010 - Neurology. 1998 Sep;51(3):682-9
– reference: 9551903 - J Immunol. 1998 Jan 15;160(2):681-90
– reference: 12925369 - Arch Neurol. 2003 Aug;60(8):1119-22
– reference: 15824253 - Arch Neurol. 2005 Apr;62(4):563-8
– reference: 9126051 - Brain. 1997 Mar;120 ( Pt 3):393-9
– reference: 23595944 - J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1186-91
– reference: 11601495 - Ann Neurol. 2001 Oct;50(4):443-51
– reference: 20182045 - J Alzheimers Dis. 2010;21(1):1-14
– reference: 2529544 - Proc Natl Acad Sci U S A. 1989 Oct;86(19):7611-5
– reference: 18558855 - Annu Rev Neurosci. 2008;31:247-69
– reference: 15794391 - Mult Scler. 2005 Apr;11(2):175-81
– reference: 20462385 - Rejuvenation Res. 2010 Apr-Jun;13(2-3):301-13
– reference: 20336135 - Nature. 2010 Mar 25;464(7288):529-35
– reference: 10496186 - J Neuroimmunol. 1999 Sep 1;99(1):131-41
– reference: 9915549 - Curr Opin Hematol. 1999 Jan;6(1):15-24
– reference: 10496180 - J Neuroimmunol. 1999 Sep 1;99(1):82-90
SSID ssj0032562
Score 2.2620912
Snippet Despite the fact that multiple sclerosis (MS) and Alzheimer's disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the...
Despite the fact that multiple sclerosis (MS) and Alzheimer's disease (AD) share common neuroimmunological features, interferon beta 1a (IFN[beta]1a), the...
Doc number: 30 Abstract: Despite the fact that multiple sclerosis (MS) and Alzheimer's disease (AD) share common neuroimmunological features, interferon beta...
Despite the fact that multiple sclerosis (MS) and Alzheimer’s disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the...
SourceID pubmedcentral
biomedcentral
proquest
gale
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 30
SubjectTerms Activities of daily living
Adjuvants, Immunologic - therapeutic use
Advertising executives
Aged
Alzheimer Disease - drug therapy
Alzheimer's disease
Analysis of Variance
Antidepressants
Antilipemic agents
Blood-brain barrier
Cholesterol
Double-Blind Method
Family medical history
Female
Free radicals
Hematology
Humans
Interferon beta-1a
Interferon-beta - therapeutic use
Male
Mental Status Schedule
Middle Aged
Neuropsychological Tests
Older people
Pathogenesis
Physiological aspects
Pilot Projects
Proteins
Retrospective Studies
Statins
Time Factors
Treatment Outcome
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4k1KQUZCKpfQJHbsWBzQClFVSOXUSnuzHD_UlbbJssle-PWdyXqXuoheYzuJPTP2N_b4G0I-CXABgvFlXmFYDVdFgWleyrwVxvLAXFVwvCh8_kucXfKf83oeN9yGGFa5mxOnidr1FvfITwC4INquVPlt9TvHrFF4uhpTaDwkj5C6DEO65HzvcDFYzqtI51M24gTAdwVaofiWuu_OFfdlsjLdnZ9vLVBp8OSt1ej0GXkaYSSdbeX-nDzw3Qvy-DwelL8kFzO6Wiz7kU70sbTvKAA9uhk87QNFioh18Gt42vrR5KWBR9Qj1TGdLf9c-cW1Xx8PNB7e0GHT4m7N8Ipcnv64-H6WxwQKeVs3xZhz51rnhauFw1gM4UWhrJUquNC0Xihla-6lL6QtvHSANRxvnQEBlVaaKhj2mhx0feffEioqJxteBy5N4AAaWiErxsC4VWG9KE1GviaDqVdbsgyN9NVpCUhVoyg0igI8EM2KjHzZDb22kZscU2Qs9eSjNOLfBp_3DXZf-m_VY5SlRoOFd1oT7x1Av5D6Ss9qBi5fAzA4I0dJTTA0mxbvtEFHQx_0X7XMyMd9MbbE4LXO95upDkycspbq3jo1443iTUbebBVs3zE8HOdMyIzIRPWSMU5LusXVRBXOFFJz1of3__o78gREyjEYvWRH5GBcb_x7wFpj-2EyqBty3yfO
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bi9UwEA66gvgi3q2uEkHQl65tc2sQkYO4LMLxySP7FtIkZQ_Udm17QH3yb_j3_CXOtD3H7bqKr8mkJXPpzDSTbwh5KiEFKG1I4wzLarhOEmzzksaFtI6XzGcJx4vCy_fyaMXfHYvj3-2AJgZ2F6Z22E9q1VYHXz5_fQ0G_2ow-Fy-gKA6A2lrPkLyXSZXwC0ptNIl3x0pMPDt2Xg7ciSecH4ueMC5u-_VzGWd_3Cf8VzzqsozburwBrk-xZd0MSrETXIp1LfI1eV0gn6bfFzQ03XV9HTAlaVNTSECpJsu0KakiB3RlqGF0SL0Nk4tDNGAGMh0UX07CetPof35_UdHp3Md2m0K_JHT3SGrw7cf3hzFU2-FuBB50sfc-8IH6YX0WKYhg0y0c0qXvsyLILV2ggcVEuWSoDyEIZ4X3oLsUqdsVlp2l-zVTR3uEyozr3IuSq5sySGeKKTKGAO714kLMrUReTljpzkdcTQMIlvPZ8DIDArDoDAgOTEsicjBlvnGTbDl2D2jMkP6kss_FzzfLdi-6a-kz1CaBrULnunsdCUB9oWoWGYhGGSDOUTIEdmfUYINuvn0Vh_MVoUNhNqYH2Y6jciT3TSuxLq2OjSbgQa-qUoo_U8awXiueR6Re6OK7TaG5-acSRURNVO-GY_nM_X6ZEARZxpRO8WD_2fXQ3INxMuxZj1l-2SvbzfhEYRkffF4MLVfCJ4wvw
  priority: 102
  providerName: Scholars Portal
Title A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects
URI https://www.ncbi.nlm.nih.gov/pubmed/24524367
https://www.proquest.com/docview/1500960291
https://www.proquest.com/docview/1501837579
https://www.proquest.com/docview/1505348948
http://dx.doi.org/10.1186/1742-2094-11-30
https://pubmed.ncbi.nlm.nih.gov/PMC3931325
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB6aBEovpe-6SRcVCunFrW3JkkVPm5IQChtKSWDpRciWTBY2dlh7L_31mbG923j7uPTigzSSkUajmdGMPgG8l-gClNbHYUJpNUJHET3zEoe5tIUouUsiQReFZxfy_Ep8nafzX2DROxH8OJOf0GROkJda9IB7e3CQCFSD5Jif_Nhsuhw1d9LffeyJBxSfP3Swc7N9OVJIu9vyPb00zpm8p4TOnsDjwXpk057dT-GBr57Bw9kQH38Ol1N2u1jWLetQY1ldMbTv2LrxrC4ZIUOsSr_C0ty3NowtFjFPCMdsuvx57Rc3fnXcsCFmw5p1Toc0zQu4Oju9_HIeDu8mhHmaRW0onMudly6VjlIwpJeRLgqlS1dmuZdaF6nwykeqiLxyaGI4kTuLfIkLZZPS8pewX9WVfw1MJk5lIi2FsqVAWyGXKuEcZVpHhZexDeDzaDLNbY-RYQi1elyDAmSIFYZYgY6H4VEAHzdTb4oBkpxexliazjXJ5O8NPmwbbP70V9Jj4qUhOcU-CztcN8BxEeKVmaYcPb0Mrd8AjkaUKF_FuHqzGswg341BM5p8v0THAbzbVlNLylmrfL3uaHC_VKnS_6RJuci0yAJ41S-w7cAoJi64VAGo0dIbzfG4plpcdwjhXBMiZ_rmv7hzCI-Q44JS1GN-BPvtau3fogXW5hPYU3M1gYOT04tv3yfdOQZ-ZyKbdFJ5B4RJLrA
linkProvider BioMedCentral
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgJeEN8EBhgJNF6y5cOxYyGECmzq2FohtEl7M4ntaJVKUppWCP4o_kbu2qQsQ-xtr7GdD9_57nfx-XcALwWGAEXmQj-itBqugoDKvIR-LjLDi9hGAaeDwsORGJzwT6fJ6Qb8bs_CUFplaxOXhtpWhv6R7yJwIbQdqfDd9LtPVaNod7UtobFSi0P38weGbPXbg48o31dRtL93_GHgN1UF_DxJg7nPrc2tEzYRlhIUhBOBMkaqwhZp7oRSJuFOukCawEmLDtjy3Gb41qGRWVRkMd73GmzyGEOZHmy-3xt9_tLa_hgBRNQQCIWp2EW4H6EeKr4iC7xwqH7S8YUXPcI5l9hN1zzn__Zvw60GuLL-StPuwIYr78L1YbM1fw-O-2w6nlRztiSsZVXJEFqyRe1YVTAipZgVboZXczfP_DDDS8wRuTLrT36dufE3N9uuWbNdxOpFTv-H6vtwciWT-wB6ZVW6R8BEZGXKk4LLrOAIU3IhozhGc6IC40SYefCmM5l6uqLn0ESY3W1BPdIkCk2iwJhHx4EHO-3Ua9OwoVNRjoleRkWp-HfA6_WA9kn_7bpNstRkIvCeJmtOOuB3EdmW7icxBpkpAm8Ptjo9cWmbbnOrDboxLbX-uxA8eLFuppGULle6arHsg6ZaJlJd2ieJeap46sHDlYKtP4y241HBpQeyo3qdOe62lOOzJTl5rIgMNHl8-as_hxuD4-GRPjoYHT6BmyheTqnwYbwFvfls4Z4i0pvnz5rlxeDrVa_oP6a-aBc
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwELZKkSpeEDeBAkZCKi9pk_iKxdNyrMrRCqEWVbxYSWyrK0Ky2mRf-PXM5FhtyvHCWxSPE2Uuz8Qznwl5ISEF8JmLwwTLariOIjzmJQ5zmRXcM5tEHBuFT07l8Tn_cCEudsjXsRdm4GDtOzhHYDLwpe_hO9zuRy87Jw4XxfejpfW97afyCOLrBASveY_Od41cV0IoNNgvr7-NHprBMp_0jZI98QD584cHXGmDLyer11UfvrWITQsst1as-S1ycwg16azXjdtkx1V3yN7JsJl-l5zN6HJR1i3tIGZpXVEIBum6cbT2FGEkVt6t4G7u2iyMM7hFHcIh01n589ItfrjVQUOHDR7arHP8o9PcI-fzd2dvjsPhkIUwF2nUhtza3DpphbRYryGdjHRRKO2tT3MntS4Ed8pFqoicshCPWJ7bDIQYFypLfMbuk92qrtxDQmViVcqF5yrzHAKLXKqEMXAAOiqcjLOAvJow0yx7QA2DENfTEZCuQVEYFAVkKYZFATkcWW-KAb8cj9EoTZfHpPL3CS83E8Y3_ZX0AGVp0KhRqbKhNwG-C-GxzEwwSAtTCJUDsj-hBGMspsOjNphBlRsDMTcmiomOA_J8M4wzscCtcvW6owHnqoTS_6QRjKeapwF50CvY5sNwA50zqQKiJqo34fF0pFpcdnDiTCN8p3j0X9J5RvY-v52bT-9PPz4mN0D4HEvbY7ZPdtvV2j2ByK3Nn3Zm-Av9uj9y
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+pilot+study+on+the+use+of+interferon+beta-1a+in+early+Alzheimer%E2%80%99s+disease+subjects&rft.jtitle=Journal+of+neuroinflammation&rft.au=Grimaldi%2C+Luigi+Maria&rft.au=Zappal%C3%A0%2C+Giuseppe&rft.au=Iemolo%2C+Francesco&rft.au=Castellano%2C+Anna&rft.date=2014-02-13&rft.issn=1742-2094&rft.eissn=1742-2094&rft.volume=11&rft.issue=1&rft.spage=30&rft_id=info:doi/10.1186%2F1742-2094-11-30&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_1742_2094_11_30
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-2094&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-2094&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-2094&client=summon